May 13, 2021
Novo Nordisk Pharma’s long-acting human growth hormone Sogroya (somapacitan) and Teijin Pharma’s osteoporosis medicine Ostabalo (abaloparatide) took a pass on the NHI reimbursement listing in May. The two agents were not on the roster of medicines presented at the Central...read more